Tonghua Dongbao - Equipment such as drug stability test chambers and constant temperature and humidity chambers are used in Tonghua Dongbao

Tonghua Dongbao Pharmaceutical Co., LtdIt is a large pharmaceutical enterprise that produces traditional Chinese and Western medicines as well as biopharmaceuticals. Established in 1985. Listed on the Shanghai Stock Exchange in 1994. As the pillar industry of Dongbao Industrial Group, the recombinant human insulin "Ganshulin" *********, which was independently developed in 1998, makes China become the three countries that can produce recombinant human insulin at home and abroad after the United States and Denmark, breaking the pattern that Chinese diabetes patients rely on imports in the use of human insulin products.
Since Gan Shulin entered the domestic market in 2003, Dongbao has always adhered to the goal of popularizing the knowledge of diabetes among rural patients and improving the diagnosis and treatment of diabetes among grassroots doctors. It has jointly undertaken a number of education projects with various societies, benefiting thousands of doctors and thousands of hospitals, and assisting the country and the society to promote the development of diabetes in China's grassroots market.
Through more than a decade of dedicated clinical teams at Dongbao, we have been deeply cultivating the human insulin market at the county level and below, surpassing foreign enterprises in terms of influence and appeal in this market. Currently, Dongbao's human insulin intake has rapidly increased from less than 0.5% to around 23%. The sales revenue increased from 3 million in 2003 to 1.4 billion yuan in 2015. The team has also grown from a few dozen people to nearly 600 people, and Gan Shulin's footprint covers more than 30 provinces and cities in China.
At present, the products sold by the company include: conventional insulin (Ganshulin R), intermediate acting insulin (Ganshulin N), 30/70 mixed recombinant human insulin injection (Ganshulin 30R), 40/60 mixed recombinant human insulin injection Ganshulin 40R, and 50/50 mixed recombinant human insulin injection Ganshulin 50R. In order to adapt to social and market changes, Dongbao has made varying degrees of progress in the research and development of four analogues (Ganshulin recombinant human insulin, Aspart insulin, Lyspro insulin, and Dexterin insulin) and human glucagon like peptide-1 (GLP-1) on the premise of improving the original product Ganshulin recombinant human insulin. In the near future, Tonghua Dongbao Company will become a domestic insulin production company with the highest dosage form.

In 2015, the company became a major shareholder of Taiwan, China Huaguang Biotechnology, and obtained the general agency right of all its blood glucose monitoring products in the mainland, marking Dongbao's comprehensive involvement in the field of diabetes blood glucose monitoring. In the same year, the company also obtained the mainland * * agency right of the latest 32G 4mm needle from Ypsomed, Switzerland, to further enrich the diabetes product chain
In 2016, Tonghua Dongbao focused on building a chronic disease management platform for doctors and patients - your doctor - on the basis of the Internet. Diabetes management encourages the effective combination of treatment and education. "Your doctor" helps doctors guide patients to actively and effectively learn diabetes diagnosis and treatment knowledge, strengthen patients' self-management, improve their living habits, promote doctor-patient communication, and strengthen the effective management of diabetes patients through the Internet platform.
With the continuous listing of follow-up new products, platform construction and expansion, Dongbao is striving to build a professional diabetes chronic disease management platform of drug treatment+blood glucose monitoring, and provide integrated solutions for the treatment of diabetes patients, striving to become a * * enterprise of drug production and services in the field of diabetes.